Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Blood cancer: Poorer prognosis due to genetic diversity of tumor cells

No. 45 | 26/09/2013 | by Koh

Blood cancers such as acute myeloid leukemia (AML) commonly exhibit the loss, exchange, or extra copies of chromosomes or portions of them. The blood of patients often contains various “daughter clones” of cancer cells with diverse chromosomal defects. Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the University Hospitals of Heidelberg and Dresden have now shown for the first time that the presence of daughter clones in AML indicates an unfavorable progression of the disease.

Bone marrow smear of acute myeloid leukemia. Alwin Krämer, German Cancer Research Center
© dkfz.de

Tumors are considered to be “clones”, i.e., common descendants of a single, mutated cell. However, cancer cells are not as uniform as one might expect from a single clone parent. Analyses of individual cells from a single tumor have often revealed an amazing genetic diversity. The majority of the differences in the genetic material affect only individual building blocks of genes. However, in many cancers, patients’ tumor cells also differ from each other in terms of large aberrations of chromosomal structure. Losses, exchanges or extra copies of entire chromosomes or parts of them can be seen under the microscope. So-called daughter clones (subclones) with diverging chromosome aberrations are particularly common in blood cancers.

“Chromosomal aberrations are frequent in acute myeloid leukemia (AML),” says Professor Dr. Alwin Krämer, who leads a Clinical Cooperation Unit of the German Cancer Research Center and Heidelberg University Hospital. “We also find distinct subclones of cancer cells in many patients. However, it was unknown whether this has any bearing on the progression of the disease in AML.”

As a project of the Study Alliance Leukemia (SAL), Krämer and his coworkers have studied the appearance of the chromosomes, called the “karyotype”, of cancer cells in more than 2,600 AML patients. The researchers detected chromosomal abnormalities in approximately 50 percent of the cases. In about one third of these, they found subclones that were distinct from each other in terms of chromosomal aberrations.

In most cases it was possible to trace the ancestry of the various clones. They were mostly “daughters” that could be distinguished from the mother clone; they had undergone a new, additional chromosomal abnormality. In some cases, a single mother clone had split off into three or more offspring clones. However, the researchers also found complex karyotypes where multiple daughter clones with various chromosomal abnormalities had arisen.

A statistical evaluation showed that the presence of subclones is associated with an unfavorable progression of the disease. In patients classified as high-risk, based on specific genetic characteristics, subclone formation turns out to be an additional, independent risk factor for an unfavorable progression. The detection of heterogeneous subclones, particularly in AML patients under 60 years of age, is therefore an independent prognostic factor for physicians.

“The formation of subclones helps tumors survive,” Alwin Krämer explains. “They enlarge their genetic spectrum, thereby increasing the chances that they will resist chemotherapy.” This hypothesis is supported by the observation that patients with an extremely large number of distinct daughter clones have an even poorer prognosis than patients who have only a few.

“These patients particularly benefit from stem-cell transplantation,” says Krämer. This type of treatment is based on immunological mechanisms, and leukemia cells seem to have greater difficulty escaping it by genetic diversification than they do when patients undergo chemotherapy.

For the first time, this analysis of AML karyotypes confirms the link between the presence of daughter clones, i.e., a tumor’s genetic diversity, and a cancer prognosis. “We assume that this phenomenon may also play a role in the ultimate health effects of other types of cancer for which heterogeneous karyotypes have been described.”

Tilmann Bochtler, Friedrich Stölzel, Christoph E. Heilig, Christina Kunz, Brigitte Mohr, Anna Jauch, Johannes W.G. Janssen, Michael Kramer, Axel Benner, Martin Bornhäuser, Anthony D. Ho, Gerhard Ehninger, Markus Schaich and Alwin Krämer for the Study Alliance Leukemia (SAL): Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. Journal of Clinical Oncology 2013, DOI: 10.1200/JCO.2013.50.7921

A picture for this press release is available on the Internet at:
http://www.dkfz.de/de/presse/pressemitteilungen/2013/images/Kraemer_AML_2.jpg

Caption: Bone marrow smear of acute myeloid leukemia. Alwin Krämer, German Cancer Research Center

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS